Insilico targeting of virus entry facilitator NRP1 to block SARS-CoV2 entry
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0310855 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Nousheen Bibi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Bioinformatics, Shaheed Benazir Bhutto Women University Peshawar, Peshawar, Pakistan. Hauptthemen laut MEDLINE: Neuropilin-1, SARS-CoV-2, Virus Internalization, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The entry and infectivity of a virus are determined by its interaction with the host. SARS-CoV-2, the virus responsible for COVID-19, utilizes the spike (S) protein to attach to and enter host cells. Recent studies have identified neuropilin-1 (NRP1) as a crucial facilitator for the entry of SARS-CoV-2. The binding of the spike protein to the b1 domain of NRP1 has been shown to enhance viral infection twofold. Consequently, targeting NRP1 to disrupt this interaction represents a promising strategy to mitigate viral infection. In this study, a small molecule library of approximately 10,000 compounds was screened to identify those that could inhibit the interaction between NRP1 and the spike protein by targeting the b1 domain of NRP1. The crystallographic structure of the b1 domain of human NRP1 (PDB entry: 7JJC) was used for this purpose. Following virtual screening, docking studies, and evaluation of binding affinity and ADMET properties, 10 compounds were shortlisted. The top two candidates, AZD3839 and LY2090314, were selected for molecular dynamics simulation studies over 100 ns to assess binding stability. MM/GBSA calculations indicated that both AZD3839 and LY2090314 exhibited strong and stable binding to the b1 domain of NRP1. Computational modeling of the interaction between the b1 domain of NRP1 and the receptor-binding domain of the spike protein suggested that AZD3839 and LY2090314 could effectively hinder the NRP1-spike interaction. Therefore, these compounds may serve as potential drug candidates to reduce SARS-CoV-2 infectivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Bioinformatics, Shaheed Benazir Bhutto Women University Peshawar, Peshawar, Pakistan.
- Department of Biomedical Sciences, College of Clinical Pharmacy, King Faisal University, Al Hofuf, Al-Ahsa Saudi Arabia.
- Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
- Faculty of Allied Health Sciences, Department of Pharmacy, Daffodil International University, Dhaka, Bangladesh.
- Enzymoics, Novel Global Community Educational Foundation, Hebersham, NSW, Australia.
ORCID-Profile: Nousheen Bibi, Mohammad Amjad Kamal
Zitieren
APA
Bibi, N., Shah, M., Khan, S., Chohan, M. S., & Kamal, M. A. (2025). Insilico targeting of virus entry facilitator NRP1 to block SARS-CoV2 entry. PLOS ONE. https://doi.org/10.1371/journal.pone.0310855
Vancouver
Bibi N, Shah M, Khan S, Chohan MS, Kamal MA. Insilico targeting of virus entry facilitator NRP1 to block SARS-CoV2 entry. PLOS ONE. 2025. doi:10.1371/journal.pone.0310855
BibTeX
@article{Bibi2025,
author = {Bibi, Nousheen and Shah, Maleeha and Khan, Shahzad and Chohan, Muhammad Shahzad and Kamal, Mohammad Amjad},
title = {Insilico targeting of virus entry facilitator NRP1 to block SARS-CoV2 entry},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0310855}
}
EUVIMED